The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

A Pfizer-Allergan marriage could prove hard on their manufacturing networks

Pfizer and Allergan are reportedly close to announcing a merger that would turn the two into the largest of the Big Pharma companies, Bloomberg has reported. They also would have the largest manufacturing network with possibly more than 100 production facilities. But Pfizer's acquisition record suggests that number would shrink significantly postmerger as it looked for ways to cut costs to pay for the massive deal.

Pfizer snags U.S. rights to Cellectis' white-hot CAR-T therapy

Pfizer has picked up the U.S. rights to Cellectis' closely watched CAR-T asset UCART19. But while Pfizer and Cellectis are working together directly on other immuno-oncology programs, the transfer of the rights to UCART19 was facilitated by a third party: Servier.

Drug distributor recalls anxiety drug after wrong med found in a bottle

Connecticut-based Breckenridge Pharmaceutical is recalling a lot of duloxetine after a single tablet of a stomach-upset drug was found in a bottle of the generic anxiety drug.

Pfizer close to record-breaking Allergan deal at up to $380 per share: Bloomberg

Pfizer and Allergan are close to striking a deal that would be the biggest of 2015 by far--and the biggest healthcare deal ever, Bloomberg reports. The price: $370 to $380 per share, or almost $150 billion.

Allergan demands CEO slot for Saunders as condition for Pfizer buyout: Forbes

If Pfizer does make a friendly deal for Allergan, CEO Ian Read will be giving up his seat at the helm. That's the word from sources at Pfizer, who told Forbes ' John LaMattina that current negotiations depend on Allergan CEO Brent Saunders taking charge at the combined company.

MSF launches vaccine pricing petition aimed at Pfizer, GSK

Médecins Sans Frontières, a global charity and frequent pharma critic, has initiated a worldwide petition calling for Pfizer and GlaxoSmithKline to reduce the prices of their pneumonia vaccines to $5 per child--for all three doses--in emerging markets and for humanitarian organizations.

Merck KGaA, Pfizer bag 'breakthrough' status for PD-L1 immunotherapy

Merck KGaA and Pfizer have bagged FDA breakthrough therapy designation for avelumab, the pair's anti-PD-L1 monoclonal antibody. And while the immunotherapy is lagging behind rivals' PD-1 and PD-L1 drugs in some indications, Merck KGaA and Pfizer think the breakthrough status could help them steal a lead in metastatic Merkel cell carcinoma.

History suggests a Pfizer-Allergan hookup would mean sizable cuts in manufacturing

The history of both Pfizer and Allergan suggests that a merger would mean headcount across the board would be trimmed and that the manufacturing network would be in line early for a haircut.

Pfizer's CMO turns to TV appearances to put a 'human face' on pharma

Dr. Freda Lewis-Hall is the chief medical officer at Pfizer and one of the company's most recognized ambassadors. She's an outspoken advocate for Pfizer and the pharma industry in general, a champion of patient empowerment and a TV medical advice star. FiercePharmaMarketing recently conducted an email interview with the psychiatrist, who also serves by Obama administration appointment to the Board of Governors for the Patient-Centered Outcomes Research Institute (PCORI).

Big Pharma warns scientific skills shortage could hold Britain back

Throughout the tough times faced by the British biopharma industry, the country could always point to its scientific excellence as a source of pride. Now, with more money swilling around, the sector should be enjoying better days, yet as financial woes have receded another resource shortage has come into view: The United Kingdom appears to be running low on scientists.